
ACTIVITY REPORT: attendance of EFOMP 2nd Symposium on Molecular Radiotherapy Dosimetry, Athens, Greece, 12-15 November

I applied for the PIANOFORTE grant to make possible my participation in the EFOMP 2nd Symposium on Molecular Radiotherapy Dosimetry in Athens. Thanks to this grant, I was able to attend the symposium in-person and present my and my colleagues research that we are developing at the Nuclear Medicine and Molecular Imaging Department of UMCG, Netherlands.

At the symposium, I have an honor to give an oral presentation titled “Population-Based Pharmacokinetic Modelling of Zr-89 Labelled Antibodies Using Non-Linear Mixed-Effects Approaches for Optimized Imaging and Quantification.” It was my first time speaking at an international conference, and the experience was both exciting and truly inspiring. The questions I received afterwards, especially from experts, helped me see new angles in future modelling work and gave me ideas for further scientific improvement.

Throughout the symposium, I participated in additional sessions focused on radiopharmaceutical dosimetry, statistics, and novel theranostic strategies. These topics are directly aligned with my current research activities and my upcoming PhD project in personalized dosimetry and pharmacokinetic modelling. The knowledge that I gained gave me a clearer understanding of novel treatment strategies, uncertainty assessment, and the practical steps needed to achieve more personalized and predictable treatment.

Another valuable aspect of symposium was the networking opportunities. I engaged in discussions with researchers from various institutions worldwide, which helped me create professional contacts and identify possibilities for future collaboration. Interaction with the bigger dosimetry and medical physics community provided to me important insights into current research directions and critical clinical needs in theranostic development.

I am truly grateful to PIANOFORTE for making this participation possible. The experience contributed significantly to my scientific growth and strengthened my motivation to continue working in personalized patient's treatment and dosimetry.